
Published at Friday, May 31, 2024 7:38 AM
Leaphy, a medical-pharmaceutical information and data intelligence company gives an answer to the actual problem that patients and health providers complains about the readability, accessibility, and accuracy of medicines information leaflet. Leaphy has developed a free app, a SaaS (software as a service) B2B product for direct access to smart leaflets (e-Pil) for the pharmaceutical industry and pharmacists in benefit for patients and healthcare providers. The electronic public productinformation data are integrated with AI via ChatGPT for medical pharmaceutical technology information. Leaphy offers services to the pharmaceutical industry as additional product data, branding, publicity and patient drug user feedback.
Summery:
1.Leaphy is in search for 500K€ capital for finishing development and starting sales in the Benelux.
2. leaphy is a start up in B2B SAAS serie A
3.Leaphy has a strong management and operational team in place
4.Leaphy has developed a technological product: The Leaphy app.
5.There is a European market supported by governemental institutes. (EMA, National Medicines Agencies,… )
6.Leaphy will be profitable on Y3
7.Recurrent business model with high profitability.
8.No or very few competition.
9.Leaphy offers an important shares participation.
There are no organizations in the network.
Leaphy has taken its fundraising offline.
Leaphy has updated its fundraising.
Geert De Pelsmaeker (Member, Leaphy) has published an article on Leaphy's page.
The pitchdeck document has been updated in the dataroom.
Leaphy has updated its fundraising.
Leaphy has published fundraising documents.
Leaphy has taken its fundraising offline.
Leaphy has been awarded the ePitches EuroQuity label.
The dataroom has been updated.
The dataroom has been updated.